# Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer

Page: https://stenobird.com/podcast/the-uromigos-1214845/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer
Text version: https://stenobird.com/podcast/the-uromigos-1214845/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer.md
Podcast: [The Uromigos](https://stenobird.com/podcast/the-uromigos-1214845)
Published: 2026-05-29T22:30:00+00:00
Episode link: https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-504-ASCO-2026---ADC-Drug-Development-in-Urothelial-Cancer-e3jsa4o
Audio file: https://anchor.fm/s/13347ea8/podcast/play/120514136/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-25%2F424851413-44100-2-cf14be68f94d8.m4a
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer
Duration seconds: 2432

## Resource

This episode with Gopa Iyer from MSKCC explores the latest advances in antibody drug conjugates (ADCs) in urothelial cancer, including data from EV302, novel ADCs targeting Nectin-4, and sequencing strategies. Experts discuss efficacy, safety, biomarkers, and future directions in bladder cancer treatment.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-uromigos-1214845/episode-504-asco-2026-adc-drug-development-in-urothelial-cancer.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.